The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
A phosphorylation-acetylation switch regulates STAT1 signaling
Open accessAbstract
Cytokines such as interferons (IFNs) activate signal transducers and activators of transcription (STATs) via phosphorylation. Histone deacetylases (HDACs) and the histone acetyltransferase (HAT) CBP dynamically regulate STAT1 acetylation. Here we show that acetylation of STAT1 counteracts IFN-induced STAT1 phosphorylation, nuclear translocation, DNA binding, and target gene expression. Biochemical and genetic experiments altering the HAT/HDAC activity ratio and STAT1 mutants reveal that a phospho-acetyl switch regulates STAT1 signaling via CBP, HDAC3, and the T-cell protein tyrosine phosphatase (TCP45). Strikingly, inhibition of STAT1 signaling via CBP-mediated acetylation is distinct from the functions of this HAT in transcriptional activation. STAT1 acetylation induces binding of TCP45, which catalyzes dephosphorylation and latency of STAT1. Our results provide a deeper understanding of the modulation of STAT1 activity. These findings reveal a new layer of physiologically relevant STAT1 regulation and suggest that a previously unidentified balance between phosphorylation and acetylation affects cytokine signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function
Torchia, J., Rose, D. W., Inostroza, J., Kamei, Y., Westin, S., Glass, C. K., & Rosenfeld, M. G. (1997) · Nature · doi:10.1038/42652 · Cited by 1,283
Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790 · cited 2×
“how STAT3 signaling is terminated (Yuan et al. 2005).”
BackgroundCrystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA
Chen, X., Vinkemeier, U., Zhao, Y., Jeruzalmi, D., Darnell, J. E., & Kuriyan, J. (1998) · Cell · doi:10.1016/s0092-8674(00)81443-9 · Cited by 720
The Stat family in cytokine signaling
Ihle, J. N. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00199-x · Cited by 713 · cited 1×
“Subsequently, STAT1 homodimers or STAT1/STAT2 heterodimers reciprocally interacting via their Src homology 2 (SH2) domains rapidly accumulate in the nucleus and induce STAT1 target genes (Ihle 2001; Platanias 2005; Stark 2007).”
BackgroundBinary switches and modification cassettes in histone biology and beyond
Fischle, W., Wang, Y., & David Allis, C. (2003) · Nature · doi:10.1038/nature02017 · Cited by 629
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523 · cited 1×
“Cells were maintained as described (Krämer et al. 2003, 2006). Transfections were done with PEI (Sigma, for 293T) or Lipofectamine (Invitrogen; as recommended). Unless stated otherwise, 1 mg DNA/12-well or 5 mg DNA/10-cm plate were transfected, and cells were harvested 48 h later. Stable cell lines were generated with…”
MethodIdentification of a Nuclear Stat1 Protein Tyrosine Phosphatase
ten Hoeve, J., de Jesus Ibarra-Sanchez, M., Fu, Y., Zhu, W., Tremblay, M., David, M., & Shuai, K. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5662-5668.2002 · Cited by 507
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Hu, X., & Ivashkiv, L. B. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.002 · Cited by 928
“The function of STATs and the transit of STAT1 through the activation-inactivation cycle are regulated by lysine acetylation (Kramer et al., 2006; Kramer et al., 2009; Nie et al., 2009; Tang et al., 2007; Yuan et al., 2005).”
BackgroundInfluentialThe Two Faces of Interferon-γ in Cancer
Zaidi, M. R., & Merlino, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0482 · Cited by 593
Histone deacetylases as regulators of inflammation and immunity
Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P., & Sweet, M. J. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.04.001 · Cited by 546
Biology and significance of the JAK/STAT signalling pathways
Kiu, H., & Nicholson, S. E. (2012) · Growth Factors · doi:10.3109/08977194.2012.660936 · Cited by 470
“…to stable dimer formation and to transcriptional activation (Bhattacharya et al. 1996; Zhang et al. 1996; Korzus et al. 1998; Paulson et al. 1999; Yuan et al. 2005); controversially, acetylation has also been suggested to facilitate dephosphorylation and latency of STAT1 (Kramer et al. 2009).”
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450
Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review
Chen, K., Liu, J., & Cao, X. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.03.008 · Cited by 312
HDAC inhibitor‐based therapies: Can we interpret the code?
New, M., Olzscha, H., & La Thangue, N. B. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 310
NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion
Lv, H., Lv, G., Chen, C., Zong, Q., Jiang, G., Ye, D., Cui, X., He, Y., Xiang, W., Han, Q., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.021 · Cited by 301
Boisson-Dupuis, S., Kong, X.-F., Okada, S., Cypowyj, S., Puel, A., Abel, L., & Casanova, J.-L. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.04.011 · Cited by 287
HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer
Stronach, E. A., Alfraidi, A., Rama, N., Datler, C., Studd, J. B., Agarwal, R., Guney, T. G., Gourley, C., Hennessy, B. T., Mills, G. B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4111 · Cited by 176
“To corroborate these finding we also looked at pSTAT1 Y701 levels in the sensitive and resistant cells by western blot.”
InfluentialHDAC2: a critical factor in health and disease
Krämer, O. H. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.007 · Cited by 157
Self-citationCross talk between stimulated NF-κB and the tumor suppressor p53
Schneider, G., Henrich, A., Greiner, G., Wolf, V, Lovas, A., Wieczorek, M., Wagner, T., Reichardt, S., von Werder, A., Schmid, R. M., et al. (2010) · Oncogene · doi:10.1038/onc.2010.46 · Cited by 149
Self-citationAn intact immune system is required for the anticancer activities of histone deacetylase inhibitors
West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0890 · Cited by 137
“translocation, thereby promoting restoration of a resting cellular state (49).”
BackgroundNFκB/p53 crosstalk—a promising new therapeutic target
Schneider, G., & Krämer, O. H. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.10.003 · Cited by 87
Self-citationMarijt, K. A., Sluijter, M., Blijleven, L., Tolmeijer, S. H., Scheeren, F. A., van der Burg, S. H., & van Hall, T. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0627-8 · Cited by 85
Baltan, S., Bachleda, A., Morrison, R. S., & Murphy, S. P. (2011) · Translational Stroke Research · doi:10.1007/s12975-011-0087-z · Cited by 85
Long, J., Fang, W. Y., Chang, L., Gao, W. H., Shen, Y., Jia, M. Y., Zhang, Y. X., Wang, Y., Dou, H. B., Zhang, W. J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.130 · Cited by 78
Adhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
Yan, Y., An, J., Yang, Y., Wu, D., Bai, Y., Cao, W., Ma, L., Chen, J., Yu, Z., He, Y., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708478 · Cited by 53
Zhao, Y., Mu, H., Huang, Y., Li, S., Wang, Y., Stetler, R. A., Bennett, M. V. L., Dixon, C. E., Chen, J., & Shi, Y. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02563-2 · Cited by 47
“Hdac3−/− bone marrow-derived macrophages underwent a cascade of changes in their inflammatory gene expression program when stimulated with lipopolysaccharides, featuring compromised interferon-β and STAT1 expression [14].”
BackgroundHistone Deacetylases in Herpesvirus Replication and Virus-Stimulated Host Defense
Guise, A., Budayeva, H., Diner, B., & Cristea, I. (2013) · Viruses · doi:10.3390/v5071607 · Cited by 43
Metadata
- Authors
- Krämer, O. H., Knauer, S. K., Greiner, G., Jandt, E., Reichardt, S., Gührs, K.-H., Stauber, R. H., Böhmer, F. D., & Heinzel, T.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2009-01-15
- Volume
- 23
- Issue
- 2
- Pages
- 223-235
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2148448562
- Cited by
- 281
- References
- 52
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.